The mAb104-MMAE ADC demonstrated equivalent efficacy at all doses assessed in a high HER2-expressing gastric cancer xenograft model, NCI-N87, with significant sustained tumour growth inhibition compared to control IgG1-MMAE (Figure 3A). This evidence concerns the gene ERBB2 and gastric cancer.